Open house discount agreements Infliximab
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
30 / 100
Facteurs de risque
No estimated value or framework maximum is provided. The actual revenue opportunity is unknown and depends on prescript...
If a nationwide or regional exclusive discount contract for Infliximab is concluded, open-house agreements terminate au...
Submission deadline in 7 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Supply of Infliximab (ATC L04AB02) pharmaceutical products to AOK Bayern under discount agreements.
- Non-exclusive framework agreements; all eligible pharmaceutical companies can participate.
Afficher le résumé complet
This is an open-house model for non-exclusive discount agreements on the active substance Infliximab (ATC L04AB02) with AOK Bayern. It is not a formal procurement procedure but a voluntary admission system under § 130a Abs. 8 SGB V. All interested pharmaceutical companies that meet the eligibility criteria can conclude identical, non-negotiable discount agreements. The earliest contract start is 01.11.2024, and all contracts end on 31.10.2026. No estimated value is provided. The procedure is classified as an open procedure in the notice but explicitly stated to be outside procurement law.
Risques
No estimated value or framework maximum is provided. The actual revenue opportunity is unknown and depends on prescript...
If a nationwide or regional exclusive discount contract for Infliximab is concluded, open-house agreements terminate au...
Submission deadline in 7 days
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Eligibility
- Only pharmaceutical companies are eligible as potential contracting partners.
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission of the signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Les exigences peuvent être incomplètes.
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open house discount agreements Infliximab
Non-exclusive discount agreements for Infliximab (ATC L04AB02) with AOK Bayern. All eligible pharmaceutical companies can join under identical terms. No selection or competition.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe kurze Beschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02
Description TED originale
Siehe kurze Beschreibung
Détails de la procédure
- Date de publication
- 16 Sep 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 558403-2024
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
30 / 100
Facteurs de risque
No estimated value or framework maximum is provided. The actual revenue opportunity is unknown and depends on prescript...
If a nationwide or regional exclusive discount contract for Infliximab is concluded, open-house agreements terminate au...
Submission deadline in 7 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications